Immunogenicity and safety of a recombinant gE-Fc fusion protein subunit vaccine for herpes zoster in adults ≥50 years of age: a randomised, active-controlled, non-inferiority trial

Journal:
Nature Communications
Published:
DOI:
10.1038/s41467-025-62800-z
Affiliations:
8
Authors:
25
Go to article
Institutions Authors Share
National Institutes for Food and Drug Control (NIFDC), China
5.000000
 0.20
Chinese Center for Disease Control and Prevention (China CDC), China
5.000000
 0.20
Zhongda Hospital, SEU, China
4.250000
 0.17
Jiangsu Provincial Center for Disease Control and Prevention (Jiangsu CDC), China CDC, China
3.083333
 0.12
Beijing Luzhu Biotechnology, China
3.000000
 0.12
State Key Laboratory for Conservation and Utilization of Bio-Resources in Yunnan, China
2.000000
 0.08
China Pharmaceutical University (CPU), China
1.583333
 0.06
Nanjing Medical University (NJMU), China
1.083333
 0.04
Interested in Clinical Sciences?